-
- 抗原 See all APOA5 抗体
- APOA5 (Apolipoprotein A-V (APOA5))
-
抗原表位
- AA 20-363
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This APOA5 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA
- 纯化方法
- Purified antibody
- 免疫原
- Purified recombinant fragment of human APOA5 (AA: 20-363) expressed in E. Coli.
- 亚型
- IgG1
- Top Product
- Discover our top product APOA5 Primary Antibody
-
anti-Apolipoprotein A-V (APOA5) (AA 167-335) antibody
APOA5 适用: 人 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Apolipoprotein A-V (APOA5) (AA 167-335) antibodyAPOA5 适用: 人 WB, IHC, IP, ICC 宿主: 小鼠 Monoclonal C11 unconjugated
anti-Apolipoprotein A-V (APOA5) (AA 21-210) antibodyAPOA5 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Apolipoprotein A-V (APOA5) (AA 21-210) antibodyAPOA5 适用: 小鼠 WB, IHC, IP, ICC 宿主: 小鼠 Monoclonal C6 unconjugated
anti-Apolipoprotein A-V (APOA5) antibodyAPOA5 适用: 人 ELISA, ICC 宿主: 小鼠 Monoclonal 2G1H11-HRP-1F1E8 unconjugated
anti-Apolipoprotein A-V (APOA5) antibodyAPOA5 适用: 人, 小鼠, 大鼠 WB, IF (p), IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Apolipoprotein A-V (APOA5) (AA 1-366) antibodyAPOA5 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Apolipoprotein A-V (APOA5) (N-Term) antibodyAPOA5 适用: 人 WB, ELISA, ICC, IF 宿主: 兔 Polyclonal unconjugated
anti-Apolipoprotein A-V (APOA5) (AA 207-366) antibodyAPOA5 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Apolipoprotein A-V (APOA5) (AA 169-367) antibodyAPOA5 适用: 大鼠 WB, IHC, ICC 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1.0 mg/mL
- 缓冲液
- PBS containing 0.03 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
-
- 抗原
- APOA5 (Apolipoprotein A-V (APOA5))
- 别名
- Apoa5 (APOA5 产品)
- 背景
- Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.
- 分子量
- 41 kDa
- 基因ID
- 116519
- UniProt
- Q6Q788
- 途径
- Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism
-
You are here:
